
The untold story about how Olive Garden's most popular special came to be
When the first Olive Garden opened in 1982 in Orlando, Florida, it was a disaster.
Long lines formed to get inside. The cooks couldn't make enough sauce to keep up with demand. Bells constantly rang, alerting the kitchen staff that a table was waiting more than 10 minutes for their meal.
The second day wasn't any better. It was immediately clear to Blaine Sweatt, an Olive Garden cofounder and general manager, that he needed a quick and cost-efficient way to satisfy hordes of hungry customers as they waited for their entrées.
Enter an endless supply of breadsticks, soups and salads.
'It made guests really happy, but it also helped the kitchen catch up since servers could get them themselves,' said Jaime Bunker, senior vice president of marketing for Olive Garden.
The special — albeit slightly tweaked to choose either soup or salad — was added to menus and included for free to guests ordering an entrée. Four decades later, the 'endless' option remains a hallmark on Olive Garden's menu.
Endless breadsticks, soup and salad are still coveted by cash-conscious guests seeking value amid economic uncertainty that's hurting the casual dining sector. The deal includes unlimited freshly baked breadsticks along with a choice of a soup (Chicken and Gnocchi, Pasta e Fagioli, Minestrone and Zuppa Toscana) or a salad.
'It's a tradition for the brand that even to this day embodies that spirit that we have of Italian generosity, of family, hospitality, of being in someone's home, where they just want nothing more than for you to have a good time and to be well fed,' Bunker told CNN.
The special has become a 'core element' to Olive Garden's identity, said Maeve Webster, president of consulting firm Menu Matters, noting that there's been 'a lot of pressure from some of the investment groups that wanted to get rid of it because of profitability and cost.'
About a decade ago, a prominent investor in Olive Garden's parent company was so fed up with the chain's sluggish sales that it released a nearly 300-page slideshow criticizing its breadsticks and sauce, suggesting changes like a management overhaul.
Some things on its menu changed as a result, but the endless breadsticks stuck around.
'You have to give Olive Garden and those running it credit for being true to that brand identity and sticking with it, even if it costs a little bit more,' Webster told CNN.
Expanding the 'endless'
Olive Garden's endless option offers value to both customers and the company, Webster said.
'It's value, from a price point of view, where you're getting an enormous amount for the money you're spending,' she said, adding that there is a benefit for Olive Garden in messaging to consumers that 'this chain is truly trying to take care of them.'
Breadsticks and soups are easy to plate and are both cost-efficient foods with high-profit margins, meaning they don't dent the chain's bottom line. Salads are a 'little higher' in cost because 'produce is a little more costly and you actually have to throw the salad together,' she said.
However, Bunker said the pricing of the three items is 'built in' to the menu costs. Darden Restaurants, the chain's parent company, is cautious about hiking prices. It only raised Olive Garden's prices by about 2% last year, which is lower than the rate of inflation.
The special was expanded into a meal option for lunch in 1991 and three years later as a dinner option. Beyond that, the popularity of those 'endless' offerings prompted Olive Garden to expand the concept to other parts of its menu.
In 1995, Olive Garden launched an unlimited pasta offer that makes yearly appearances, except for a brief break during the height of the Covid-19 pandemic. The 'Never Ending Pasta Bowl' promotion happens around the back-to-school time in the fall when 'people have a lot of expenses' and 'consumers are looking to save,' Bunker added.
Focus on value
Value options for customers, notably the return of its buy-one meal and get a take-home meal deal following a five-year hiatus, helped raise Olive Garden's sales by 6.9% in its most recent quarter.
That was the chain's best same-store sales performance in three years and a sharp reversal from the 2.9% decline it experienced in the same quarter a year ago.
Darden doesn't expect growth to remain that high, but it is forecasting a solid 2% to 3.5% rise in same-store sales for the next year. Similar to Chili's, Olive Garden says it's seeing customers revisit the chain because it offers a better value compared to fast food and grocery shopping.
'Our consumers want to go out and spend their hard-earned money, and we think we're taking some wallet share from fast food and fast casual,' Darden CEO Rick Cardenas said on call with analysts in June.
Olive Garden is adding more lower-priced options in the coming months and isn't planning any additional price increases, executives said on the call. Darden's (DRI) stock is up nearly 20% for the year.
Part of Olive Garden's success, in Webster's opinion, is that the chain hasn't 'allowed themselves to get too distracted by the relentless pursuit of trends that the industry finds itself in.'
Bunker said Olive Garden has no plans to tinker with or axe the endless soup or salad and breadsticks option — and confirmed that there's no limit to how much a guest can order in one sitting.
'We're very committed to giving our guests never-ending, abundant, crave-able Italian food at an everyday value,' she said. 'It's just part of who the brand is.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Associated Press
12 minutes ago
- Associated Press
DentScribe Launches GPS - AI-Powered "Guided Production System" Transforming Dental Practice Operations and Revenue Optimization
SAN JOSE, Calif., July 6, 2025 /PRNewswire/ -- today announced the launch of DentScribe GPS (Guided Production System), a groundbreaking addition to its AI-powered dental software suite, building upon the successful DentScribe CoPilot. DentScribe GPS provides dental practices with a comprehensive, practice-wide view of patient care, production opportunities, and actionable insights drawn directly from the dentist's AI-generated SOAP notes. Unlike traditional dashboards based on static diagnostic imaging (e.g., x-rays), DentScribe GPS leverages the dentist's own professional assessments captured in SOAP notes, reflecting the 'ground truth' of clinical needs and treatment plans. This real-time AI analysis ensures precise identification of high-value production opportunities, urgent patient care interventions, and daily operational priorities. DentScribe GPS delivers its insights through a user-friendly, tablet-first interface specifically optimized for morning huddles and daily planning sessions. Dental teams gain immediate visibility into critical alerts, planned production, patient follow-ups, and comprehensive practice performance metrics. DentScribe GPS visually categorizes opportunities by urgency, provider, discipline, and financial value, empowering teams to prioritize effectively. Dr. Vinni K. Singh, DDS, founder and CEO of remarked, 'DentScribe GPS changes everything about our morning huddles. We now start each day knowing exactly where to focus our efforts to maximize both patient care and practice profitability. By harnessing AI-driven insights directly from our SOAP notes, we are identifying care opportunities and revenue streams that diagnostic tools alone simply cannot see.' Early adopters report significant practice improvements, including: DentScribe GPS includes a unique Daily Brief (DentScribe GPS Intelligence), which provides a concise summary of critical daily priorities, revenue optimization strategies, and team productivity goals. Dental teams can quickly review key insights and make informed decisions at the start of each day. DentScribe GPS is now available nationwide, building upon the success of DentScribe CoPilot and further establishing DentScribe as the market leader in AI-driven dental practice management. To see DentScribe GPS in action and experience immediate, measurable results in your dental practice, schedule a demo today at Media Contact: [email protected] View original content to download multimedia: SOURCE DentScribe
Yahoo
31 minutes ago
- Yahoo
Gas prices in Massachusetts declined from last week: Find out how much.
State gas prices declined last week and reached an average of $3.02 per gallon of regular fuel on Monday, down from last week's price of $3.07 per gallon, according to the U.S. Energy Information Administration. The average fuel price in state rose about 7 cents since last month. According to the EIA, gas prices across the state in the last year have been as low as $2.88 on April 14, 2025, and as high as $3.50 on July 8, 2024. A year ago, the average gas price in Massachusetts was 14% higher at $3.50 per gallon. >> INTERACTIVE: See how your area's gas prices have changed over the years at . The average gas price in the United States last week was $3.16, making prices in the state about 4.5% lower than the nation's average. The average national gas price is lower than last week's average of $3.21 per gallon. The USA TODAY Network is publishing localized versions of this story on its news sites across the country, generated with data from the U.S. Energy Information Administration. Please leave any feedback or corrections for this story here. This story was written by Ozge Terzioglu. Our News Automation and AI team would like to hear from you. Take this survey and share your thoughts with us. This article originally appeared on Standard-Times: Massachusetts gas prices declined from last week: See how much here
Yahoo
37 minutes ago
- Yahoo
Morgan Stanley Raises PT on Apellis Pharmaceuticals (APLS) to $26, Keeps a Hold Rating
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On July 1, analyst Judah Frommer from Morgan Stanley raised the firm's price target on Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) to $26.00 from $25.00 while maintaining a Hold rating on the stock. Frommer attributed the rating to the company's market position and recent financial strategies. A biomedical scientist in a lab coat conducting research on biopharmaceutical compounds. He cited the company's significant royalty purchase agreement with Sobi, securing up to $300 million and including a $275 million upfront payment, stating that it would slash Sobi's royalty obligations on Aspaveli sales by 90%. This would result in immediate financial benefits for Apellis and may even ease investor concerns regarding the company's profitability. Despite this positive development, Frommer maintained a cautious outlook for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) due to its future prospects. He stated that while the anticipated regulatory decisions from the FDA and CHMP and the launches of Empaveli/Aspaveli in new indications are significant events, they bring in as much uncertainty as confidence in the company's market potential. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is a commercial-stage biopharmaceutical company that discovers, develops, and commercializes novel therapeutic compounds for treating diseases with unmet needs. Its product portfolio primarily includes EMPAVELI and SYFOVRE. SYFOVRE treats geographic atrophy secondary to age-related macular degeneration (GA), while EMPAVELI treats paroxysmal nocturnal hemoglobinuria (PNH). While we acknowledge the potential of APLS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data